| Drug Type AAV based gene therapy | 
| Synonyms- | 
| Target | 
| Action modulators | 
| Mechanism DWORF modulators(small transmembrane regulator of ion transport 1 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Cardiomyopathy, Dilated | Preclinical | - | 23 Jan 2024 | |
| Heart failure with reduced ejection fraction | Preclinical | - | 23 Jan 2024 | |
| Cardiomyopathies | Preclinical | United States  | - | |
| Heart Failure | Preclinical | United States  | - | 





